Full Press Release Details
Lexaria Announces Million Dollar Research and Development
Kelowna, BC / May 2, 2017 / Lexaria Bioscience Corp
(OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) announces a $1 million
combined research and development ( R&D ) and intellectual property ( IP )
Lexaria s R&D program is expected to begin in June 2017 and
be comprised of studies both inclusive of and also complementary to its
collaborative R&D with Canada s National Research Council ( NRC ). Lexaria s
R&D budget is fully funded from existing capital, applying existing funds.
The Lexaria R&D will include many studies; and their
objectives, design, and results will be reported as available. Lexaria s patent
applications name several groups of molecules, all of which will be studied
The R&D will include in vitro absorption studies
utilizing Lexaria s technology to examine improvements in absorption across
human intestinal tissue. For the first time ever Lexaria will also conduct in
vivo (animal) studies, designed to provide more detailed information on
whole-body reactions to efficient and rapid delivery of these various payload
molecules. The in vivo studies are expected to significantly advance
Initial in vitro human intestinal cell absorption
studies conducted by the Company in 2015 for non-psychoactive cannabinoids
reported increases in cannabinoid absorption at that time in the range of 325%
The complete R&D program of 2017 and 2018 represents
roughly a 10-fold increase in the third-party laboratory work previously
contracted by Lexaria and is expected to provide the foundation for increased
licensing opportunities in market sectors as yet untouched by Lexaria. The
Company expects many new business opportunities to arise as a result of
successful R&D results.
Included within this budget is intellectual property pursuit in
the USA, Canada and around the world. Lexaria currently has a total of 18
patents pending, and patent applications filed in more than 40 countries around
the world. Lexaria s existing financial resources are sufficient to aggressively
pursue positive outcomes within this large IP portfolio.
Additional information on planned R&D programs will be
Lexaria Bioscience Corp. is a food biosciences company with a
proprietary technology for improved delivery of bioactive compounds. The
Company s lipophilic enhancement technology has been shown to enhance the
bioavailability of orally ingested cannabinoids, while also masking taste. This
technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. www.lexariabioscience.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Factors which could cause actual results to differ materially from
those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance that Lexaria will successfully complete any other
contemplated or existing technology license agreements, nor that Lexaria s
technology will deliver any improvement in taste or bioavailability with any
reliability nor across any product category. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever, nor that any patent application in the USA or any
other nation or under any treaty will result in the award of an actual patent;
nor that an award of any actual patent will protect against challenges from
unknown third parties. There is no assurance that any of Lexaria s postulated
uses, benefits, or advantages for the patent-pending technology will in fact be
realized in any manner or in any part. No statement herein has been evaluated by
the Food and Drug Administration (FDA)or by Health Canada. Lexaria products are
not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.